Incretin Therapy and Beta Cell Mass
Posted May 25, 2011 by Patricia Brubaker, PhDAnalyses of human pancreata have demonstrated that type 2 diabetes is associated not only with a loss of beta cell function, but also with a marked decrease in beta cell volume.[1] Intriguingly, data from rodent studies have convincingly shown that GLP-1 and long-acting GLP-1 receptor agonists, including exenatide and liraglutide, increase both beta cell function and beta cell mass under physiological conditions as well as in models of diabetes.